Abstract 392: Incidence Of Paroxysmal Supraventricular Tachycardia In The United States

2020 ◽  
Vol 13 (Suppl_1) ◽  
Author(s):  
Michael Rehorn ◽  
Naomi Sacks ◽  
Madison Preib ◽  
Philip Cyr ◽  
Maia Emden ◽  
...  
Keyword(s):  
United States ◽  
Incidence Rate ◽  
Supraventricular Tachycardia ◽  
Older Patients ◽  
The United States ◽  
Paroxysmal Supraventricular Tachycardia ◽  
Research Database ◽  
Heart Rhythm Disorders ◽  
Us Census ◽  
Incident Cases

Background: Paroxysmal supraventricular tachycardia (PSVT) encompasses a range of heart rhythm disorders that lead to abrupt increases in heart rate. Given its episodic nature, PSVT can be difficult to capture in a clinical setting. Therefore, estimating incidence of PSVT is challenging and thus limited data is available on the incidence of this disease. Objective: Estimate the incidence of PSVT within the United States in contemporary practice. Methods: Using claims, enrollment, and demographic data from the IBM Marketscan® Commercial Research Database (<65y) and the Medicare Limited Dataset (≥65y), individuals enrolled in health plans for at least 5 continuous years from 2008-2016 were identified. Patients having claims with a PSVT diagnosis (ICD-9: 427.0; ICD-10 I47.1) on 2+ outpatient visits, 1+ ED visit, or 1+ inpatient admission were included in the analysis. Only patients receiving an initial diagnosis of PSVT in year 5 of continuous enrollment were included in the incidence calculation in order to avoid including prevalent cases. Incidence was projected to the US population based on the 2018 US census data. Results: Among 18,057,297 patients, 86,614 met PSVT criteria. Incidence rates were higher in female and older patients. Within the 18-44y group, the incidence rate was 1.9-fold higher for females as compared to males. Overall incidence rate per 100,000 was 79.1 and 107.2 for males and females respectively (Table). Projected to the 2018 US Census, there were 305,548 incident PSVT cases in 2018. Conclusion: There were over 305,000 incident cases of PSVT in 2018 with higher rates in female and older patients. Further studies are needed to understand practice patterns in management of PSVT, given the high incidence of this disease.

Medicaid Expansion and Incidence of Kidney Failure among Nonelderly Adults

2021 ◽  
pp. ASN.2020101511
Author(s):  
Rebecca Thorsness ◽  
Shailender Swaminathan ◽  
Yoojin Lee ◽  
Benjamin D. Sommers ◽  
Rajnish Mehrotra ◽  
...  
Keyword(s):  
United States ◽  
Incidence Rate ◽  
Kidney Failure ◽  
The United States ◽  
Early Years ◽  
Relative Reduction ◽  
Medicaid Expansion ◽  
Expansion Time ◽  
Incident Cases ◽  
Medicaid Expansions

BackgroundLow-income individuals without health insurance have limited access to health care. Medicaid expansions may reduce kidney failure incidence by improving access to chronic disease care.MethodsUsing a difference-in-differences analysis, we examined the association between Medicaid expansion status under the Affordable Care Act (ACA) and the kidney failure incidence rate among all nonelderly adults, aged 19–64 years, in the United States, from 2012 through 2018. We compared changes in kidney failure incidence in states that implemented Medicaid expansions with concurrent changes in nonexpansion states during pre-expansion, early postexpansion (years 2 and 3 postexpansion), and later postexpansion (years 4 and 5 postexpansion).ResultsThe unadjusted kidney failure incidence rate increased in the early years of the study period in both expansion and nonexpansion states before stabilizing. After adjustment for population sociodemographic characteristics, Medicaid expansion status was associated with 2.20 fewer incident cases of kidney failure per million adults per quarter in the early postexpansion period (95% CI, −3.89 to −0.51) compared with nonexpansion status, a 3.07% relative reduction (95% CI, −5.43% to −0.72%). In the later postexpansion period, Medicaid expansion status was not associated with a statistically significant change in kidney failure incidence (−0.56 cases per million per quarter; 95% CI, −2.71 to 1.58) compared with nonexpansion status and the pre-expansion time period.ConclusionsThe ACA Medicaid expansion was associated with an initial reduction in kidney failure incidence among the entire, nonelderly, adult population in the United States; but the changes did not persist in the later postexpansion period. Further study is needed to determine the long-term association between Medicaid expansion and changes in kidney failure incidence.

PRESENT STATUS AND TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA

PEDIATRICS ◽  
1972 ◽  
Vol 50 (1) ◽  
pp. 127-130
Author(s):  
Leonard M. Linde ◽  
Searle W. Turner ◽  
Shoichi Awa
Keyword(s):  
United States ◽  
Supraventricular Tachycardia ◽  
Present Status ◽  
The United States ◽  
Therapeutic Agents ◽  
Paroxysmal Supraventricular Tachycardia ◽  
Adrenergic Blockade ◽  
New Agents ◽  
Beta Adrenergic ◽  
Highly Effective

The therapeutic agents that have been described will successfully convert close to 100% of all episodes of PST in children. Digoxin is the most frequently used agent for treatment of acute PST and is highly effective and safe. Recently, cardioversion and beta-adrenergic blockade are being employed more frequently, both with specific indications. Newer electrical means and new agents such as Verapamil are effective but the former are not yet widely used and the latter not yet authorized for use in the United States. Prophylaxis of recurrent episodes is usually successful with digoxin, with the addition or substitution of propranolol in certain conditions.

scholarly journals Monetizing the Burden of Childhood Asthma Due to Traffic Related Air Pollution in the Contiguous United States in 2010

2021 ◽  
Vol 18 (15) ◽  
pp. 7864
Author(s):  
Minaal Farrukh ◽  
Haneen Khreis
Keyword(s):  
United States ◽  
Air Pollution ◽  
Economic Impact ◽  
Childhood Asthma ◽  
Ambient Air ◽  
The United States ◽  
The State ◽  
Cost Calculation ◽  
Cost Burden ◽  
Incident Cases

Background: Traffic-related air pollution (TRAP) refers to the wide range of air pollutants emitted by traffic that are dispersed into the ambient air. Emerging evidence shows that TRAP can increase asthma incidence in children. Living with asthma can carry a huge financial burden for individuals and families due to direct and indirect medical expenses, which can include costs of hospitalization, medical visits, medication, missed school days, and loss of wages from missed workdays for caregivers. Objective: The objective of this paper is to estimate the economic impact of childhood asthma incident cases attributable to nitrogen dioxide (NO2), a common traffic-related air pollutant in urban areas, in the United States at the state level. Methods: We calculate the direct and indirect costs of childhood asthma incident cases attributable to NO2 using previously published burden of disease estimates and per person asthma cost estimates. By multiplying the per person indirect and direct costs for each state with the NO2-attributable asthma incident cases in each state, we were able to estimate the total cost of childhood asthma cases attributable to NO2 in the United States. Results: The cost calculation estimates the total direct and indirect annual cost of childhood asthma cases attributable to NO2 in the year 2010 to be $178,900,138.989 (95% CI: $101,019,728.20–$256,980,126.65). The state with the highest cost burden is California with $24,501,859.84 (95% CI: $10,020,182.62–$38,982,261.250), and the state with the lowest cost burden is Montana with $88,880.12 (95% CI: $33,491.06–$144,269.18). Conclusion: This study estimates the annual costs of childhood asthma incident cases attributable to NO2 and demonstrates the importance of conducting economic impacts studies of TRAP. It is important for policy-making institutions to focus on this problem by advocating and supporting more studies on TRAP’s impact on the national economy and health, including these economic impact estimates in the decision-making process, and devising mitigation strategies to reduce TRAP and the population’s exposure.

scholarly journals Temporal trends in percutaneous coronary intervention outcomes among older patients in the United States

2013 ◽  
Vol 166 (2) ◽  
pp. 273-281.e4 ◽  
Author(s):  
Sunil V. Rao ◽  
Connie N. Hess ◽  
David Dai ◽  
Cynthia L. Green ◽  
Eric D. Peterson ◽  
...  
Keyword(s):  
United States ◽  
Percutaneous Coronary Intervention ◽  
Older Patients ◽  
Temporal Trends ◽  
Coronary Intervention ◽  
The United States ◽  
Percutaneous Coronary

EPID-10. GLIOMA INCIDENCE AND SURVIVAL BY INCOME LEVEL IN THE UNITED STATES GENERAL POPULATION AGES AND ABOVE FROM 2000-2018

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi87-vi88
Author(s):  
Jennifer Murillo ◽  
Elizabeth Anyanda ◽  
Jason Huang
Keyword(s):  
United States ◽  
General Population ◽  
Survival Data ◽  
Survival Rates ◽  
The United States ◽  
Income Level ◽  
Population Based ◽  
Research Database ◽  
Income Levels ◽  
Average Survival

Abstract Gliomas are the most common primary malignant brain tumor in the United States with previous studies showing the incidence varied by age, sex, and race or ethnicity. Survival after diagnosis has also been shown to vary by these factors. Also, socioeconomic status and its association with various cancers have also been studied at length over time. PURPOSE: The purpose of our research was to quantify the differences in incidence and survival rates of gliomas in 15 years and older by income level. METHODS: This population-based study obtained incidence and survival data from the Incidence-SEER Research Database the general population. Average age incidence were generated by glioma groups and grouped by income levels. Survival rates were generated by overall glioma diagnosis grouped by observed survival at 12, 24, 36, 48 and 60 months and by again by income levels. The analysis included 94,207 patients with glioma diagnosed in those aged 15 years or older. RESULTS: Overall, 94, 207 patients diagnosed with glioma were analyzed. Of these, 1,089 (1.16%) fell into the &lt; $35k group, 1,684 (1.79%) in the $35k-$40k group, 3,473 (3.69%) in the $40k-$45k group, 5,647 (5.99%) in the $45k-$50k group, 7,138 (7.58%) in the $50k-$55k group, 6,468 (6.87%) in the $55k-$60k group, 15,348 (16.29%) in the $60k-$65k group, 13,216 (14.03%) in the $65k-$70k group, 9,035 (9.59%) in the $70k-$75k group, and 31,109 (33.02%) fell in &gt; $75k group. The data was also broken further down into survivability showing average survival. CONCLUSION: Incidence of glioma and 12, 24, 36, 48 and 60 month survival rates after diagnosis vary significantly by income level with higher income level greater than $75,000+ having higher incidence and higher survival rates compared with lower income levels. Further research is needed to help determine risk factors and barriers to care to help reveal health disparities.

Sign in / Sign up

Export Citation Format

Share Document